Baxa Corporation, a global provider of innovative medical solutions for pharmacy automation, has declared that for four successive years, Baxa has been enlisted on the Inc.5000 list of emerging private firms in United States, currently holding the 3494th rank.
Greg Baldwin, Baxa Chairman and CEO, has stated that this development is enabled by its sustained emphasis on development of automation technology in medical applications thereby offering a high level of assurance and security in IV dose preparation. This has greatly helped in entering into the market and holding the reputation for superior quality.
A leading magazine Pharmacy Purchasing & Products (PP&P), conducted a market survey with more than 400 directors of pharmaceutical companies. The outcome of this evaluation states that more than 75% share of robots that are employed in IntelliFill i.v. system are retained by Baxa Corporation. The company also holds more than 68% share of automated devices used with ExactaMix Automated Compounders. Baxa also owns 50% contribution of IV workflow management work performed in DoseEdge Pharmacy with 64% share of seller consideration. In addition to this, Baxa’s automation products are utilized globally in more than 3000 hospitals for the preparation of around 450,000 ideal drug doses.
PP&P’s Publisher, R. Mitchell Halvorsen has remarked in his article, "Signs of an Automation Rebound in 2010,” that the significance of automation cannot be ignored which is clearly specified by the recent trends in health care capitalization.
To meet with the growing expansion in manufacture, Baxa has acquired a new office and laboratory space of 64,000 sq feet at 9540 S Maroon Circle, Englewood, Colorado.